Login
Navigate Fool.com
Will VVUS beat
the market?

VIVUS, Inc. (NASDAQ: VVUS)

Community Rating: 2 Stars: Unattractive

4.77 -0.13 (-2.65%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $4.87
Previous Close $4.90
Daily Range $4.79 - $4.91
52-Week Range $4.53 - $15.15
Market Cap $492.8M
P/E Ratio -3.66
Dividend (Yield) $0.00 (0.0%)
Volume 360,223
Average Daily Volume 1,683,187
Current FY EPS -$1.17

How do you think VVUS
will perform against the market?

Top VVUS Bull/Bear Pitches

 

geomedf (6.94)
Submitted February 23, 2012

Qnexa on fast track to fda approval.

25 Replies Reply Report this Post
 

boyceh66 (< 20)
Submitted July 19, 2010

I am in this business, and have spent countless hours analyzing the 3 competing obesity drug companies that have FDA action dates this year. The only people who praise Qnexa's great results and the ot … More

1 Replies Reply Report this Post

News & Commentary Rss Feed

The Implications of Obesity as a Disability in Europe

Despite rising obesity in Europe, the EU has yet to approve weight loss drugs from Arena (ARNA), Vivus (VVUS), or Orexigen (OREX).

Arena Pharmaceuticals Inc. Still Down After CEO's Sale

It says something about the short-term prospects for Arena Pharmaceuticals. And competitors, Orexigen and VIVUS, for that matter.

3 Crashing Biotechs: Is 1 a Buy?

Here's why Aegerion (AEGR), Vivus (VVUS), and Exelixis (EXEL) are healthcare's worst performers this year.

3 Stocks Even Volatility-Loving Nasdaq Investors Hate

The Nasdaq Composite may be hitting a multidecade high, but pessimists are piling into these three Nasdaq-listed stocks. Are things really as bad as these short-interest figures indicate?

The Next Orphan Drug Multibagger and Future Obesity Champion?

Zafgen's arrival on public markets shakes up the obesity drug war

Are Investors Wrong About Orexigen Therapeutics?

Short-sellers are moving into Orexigen Therapeutics ahead of the company's PDUFA date for its flagship obesity drug. Here's why.

Are Investors Wrong About VIVUS?

Short-sellers have starting piling into VIVUS. Here's why.

How Bad Is This Delay for Orexigen Therapeutics, Inc?

Delayed approval of Orexigen Therapeutics' Contrave won't hurt the company much, and it won't help competitors Arena Pharmaceuticals and VIVUS, either.

FDA Drops the Hammer on Twitter

New FDA regulations makes pharma companies describe benefits and risks of drugs in 140 characters

Is This Arena Pharmaceuticals' Biggest Risk?

Could this historical trend for fat-fighting pills sink Arena Pharmaceuticals?

See More VVUS News...

Sector

Healthcare

Industry

Drugs

VIVUS, Inc. (VVUS) Description

A pharmaceutical company dedicated to the development and commercialization of therapeutic products using patented proprietary formulations and novel delivery systems and by seeking new indications for previously approved pharmaceutical products. Website: http://www.vivus.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks